After a generation of failures, the drug industry has pivoted to its next-best idea for treating Alzheimer’s disease. But a troubling string of clinical trial results suggests that the latest approach to the devastating disease might go the way of its forebears, continuing decades of frustration for patients and scientists.

Over the past year, three clinical trials involving two similar medicines have been halted early, two because a drug was clearly not working and a third because the treatment came with worrying safety concerns.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Sorry, I signed up for the STAT News, but I didn’t see any place to type in a password & now I can’t sign in. Help? Thank you, Carmen

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy